ALVO
Price
$4.38Alerts
Change
-$0.03 (-0.68%)
Updated
Nov 17, 04:59 PM (EDT)
Capitalization
1.73B
113 days until earnings call
Intraday BUY SELL Signals
CRON
Price
$3.20Alerts
Change
-$0.07 (-2.14%)
Updated
Nov 17, 04:59 PM (EDT)
Capitalization
1.33B
107 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALVO vs CRON

ALVO vs CRON Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ALVO vs. CRON commentary
Nov 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALVO is a Hold and CRON is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ALVO with price predictions
Nov 16, 2026

ALVO in -14.84% downward trend, declining for three consecutive days on November 13, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ALVO declined for three days, in 233 of 294 cases, the price declined further within the following month. The odds of a continued downward trend are 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALVO as a result. In 71 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.

The Moving Average Convergence Divergence Histogram (MACD) for ALVO turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 33 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.

ALVO moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ALVO crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.

The Aroon Indicator for ALVO entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ALVO's RSI Oscillator exited the oversold zone, 25 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALVO advanced for three days, in 199 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

ALVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-9.057) is normal, around the industry mean (6.379). P/E Ratio (-7.839) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.071) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. ALVO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

A.I.Advisor
a Summary for CRON with price predictions
Nov 16, 2026

CRON's Stochastic Oscillator sits in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for CRON crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.

Following a +10.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in 170 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

The Aroon Indicator entered an Uptrend today. In 97 of 131 cases where CRON Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.

Bearish Trend Analysis

The 10-day RSI Indicator for CRON moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 21 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRON as a result. In 87 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for CRON turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 61 similar instances when the indicator turned negative. In 45 of the 61 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

CRON moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.

CRON broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. CRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.245) is normal, around the industry mean (6.379). P/E Ratio (19.000) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (6.993) is also within normal values, averaging (183.387).

The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

FUNDAMENTALS RATINGS
ALVO vs CRON: Fundamental Ratings
ALVO
CRON
OUTLOOK RATING
1..100
887
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
52
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10080
PRICE GROWTH RATING
1..100
6040
P/E GROWTH RATING
1..100
9864
SEASONALITY SCORE
1..100
8511

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALVO's Valuation (7) in the null industry is somewhat better than the same rating for CRON (52) in the Pharmaceuticals Other industry. This means that ALVO’s stock grew somewhat faster than CRON’s over the last 12 months.

ALVO's Profit vs Risk Rating (100) in the null industry is in the same range as CRON (100) in the Pharmaceuticals Other industry. This means that ALVO’s stock grew similarly to CRON’s over the last 12 months.

CRON's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as ALVO (100) in the null industry. This means that CRON’s stock grew similarly to ALVO’s over the last 12 months.

CRON's Price Growth Rating (40) in the Pharmaceuticals Other industry is in the same range as ALVO (60) in the null industry. This means that CRON’s stock grew similarly to ALVO’s over the last 12 months.

CRON's P/E Growth Rating (64) in the Pharmaceuticals Other industry is somewhat better than the same rating for ALVO (98) in the null industry. This means that CRON’s stock grew somewhat faster than ALVO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALVOCRON
RSI
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 7 days ago
74%
Bullish Trend 13 days ago
73%
Declines
ODDS (%)
Bearish Trend 5 days ago
79%
Bearish Trend 2 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
74%
COMPARISON
Comparison
Nov 17, 2026
Stock price -- (ALVO: $4.41 vs. CRON: $3.27)
Brand notoriety: ALVO and CRON are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALVO: 91% vs. CRON: 104%
Market capitalization -- ALVO: $1.73B vs. CRON: $1.33B
ALVO [@Pharmaceuticals: Generic] is valued at $1.73B. CRON’s [@Pharmaceuticals: Generic] market capitalization is $1.33B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALVO’s FA Score shows that 1 FA rating(s) are green while CRON’s FA Score has 0 green FA rating(s).

  • ALVO’s FA Score: 1 green, 4 red.
  • CRON’s FA Score: 0 green, 5 red.
According to our system of comparison, CRON is a better buy in the long-term than ALVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALVO’s TA Score shows that 4 TA indicator(s) are bullish while CRON’s TA Score has 4 bullish TA indicator(s).

  • ALVO’s TA Score: 4 bullish, 6 bearish.
  • CRON’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, both ALVO and CRON are a bad buy in the short-term.

Price Growth

ALVO (@Pharmaceuticals: Generic) experienced а -6.08% price change this week, while CRON (@Pharmaceuticals: Generic) price change was -7.63% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -4.48%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -7.77%.

Reported Earning Dates

ALVO is expected to report earnings on Mar 10, 2027.

CRON is expected to report earnings on Mar 04, 2027.

Industries' Descriptions

@Pharmaceuticals: Generic (-4.48% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

ALVO and

Correlation & Price change

A.I.dvisor tells us that ALVO and EBS have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALVO and EBS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALVO
1D Price
Change %
ALVO100%
+5.13%
EBS - ALVO
30%
Poorly correlated
+0.35%
CRON - ALVO
24%
Poorly correlated
-3.25%
XERS - ALVO
23%
Poorly correlated
+0.24%
PAHC - ALVO
22%
Poorly correlated
-2.64%
SIGA - ALVO
22%
Poorly correlated
+4.01%
More

CRON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRON has been closely correlated with SNDL. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRON jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRON
1D Price
Change %
CRON100%
-3.25%
SNDL - CRON
73%
Closely correlated
-2.19%
TLRY - CRON
57%
Loosely correlated
-3.70%
CGC - CRON
55%
Loosely correlated
-2.71%
ACB - CRON
55%
Loosely correlated
-6.68%
TRLV - CRON
55%
Loosely correlated
-5.23%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VSEC181.910.29
+0.16%
VSE Corp
MSGM3.90-0.01
-0.26%
Motorsport Games
MCBS36.12-0.38
-1.04%
MetroCity Bankshares
TRGP292.12-5.21
-1.75%
Targa Resources Corp
ACIU2.09-0.04
-1.88%
AC Immune SA